Showing 7561-7570 of 8465 results for "".
- Pre-conditioning Added to Sebacia Microparticles Enhances Outcomeshttps://practicaldermatology.com/news/pre-conditioning-added-to-sebacia-microparticles-enhances-outcomes/2457567/Using pre-conditioning in conjunction with Sebacia Microparticles for treatment of acne leads to enhanced outcomes, new data suggest. In fact, results from a real-world, pre-conditioning registry trial in Europe demonstrate that the combination of pre-conditioning followed by Sebacia Mi
- Study: Positive Safety and Tolerability Results for Ortho Dermatologics' Altreno for Acnehttps://practicaldermatology.com/news/study-positive-results-for-ortho-dermatologics-altrenos-safety-and-tolerability-for-acne/2457569/Ortho Dermatologics shared results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of Altreno (tretinoin) Lotion, 0.05%, the first formulation of tretinoin, a retinoid, in a lotion indicated for the topi
- Galderma Ups Its Aesthetic R&D Gamehttps://practicaldermatology.com/news/galderma-ups-their-aesthetic-r-d-game/2457570/Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport evaluating patient satisfaction and
- Online Care May Be As Effective as In-Person Care for Psoriasishttps://practicaldermatology.com/news/online-care-may-be-as-effective-as-in-person-care-for-psoriasis/2457574/Teledermatology may be as effective as seeing a doctor in person when it comes to improving the symptoms of psoriasis, according to a new study in JAMA Network Open. “Patients with chronic skin diseases need ongoing care, and depending on where they live, their access to de
- EPI Acquires Rights to Cloderm Cream from Promius Pharmahttps://practicaldermatology.com/news/epi-acquires/2457576/EPI Health has acquired the rights rights to Cloder
- FDA Approves Paratek's Nuzyrahttps://practicaldermatology.com/news/fda-approves-parateks-nuzyra/2457579/The FDA has approved Paratek Pharmaceuticals, Inc's Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). Nuzyra, a modernized tetracycline, is a once-daily IV and or
- Veloce BioPharma Announces Positive Phase 2b Study Results for VBP-926 for Chemotherapy-Associated Paronychiahttps://practicaldermatology.com/news/veloce-biopharma-announces-positive-phase-2b-study-results-for-vbp-926-for-chemotherapy-associated-paronychia/2457580/Veloce BioPharma, LLC, a clinical-stage biopharmaceutical company dedicated to developing topical therapeutics for unmet needs in dermatologic and ophthalmic diseases, shared positive results of its Phase 2b study of dilute povidone-iodine in a novel DMSO solvent system for the topical treatment
- Seysara: Oral Antibiotic is First Approved for Dermatology in 40 Yearshttps://practicaldermatology.com/news/seysara-oral-antibiotic-is-first-approved-for-dermatology-in-40-years/2457584/Seysara (sarecycline), a new, first in class tetracycline-derived oral antibiotic, is now approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Almirall, which recently acquired Seysara from Allergan, plans to laun
- RealSelf Survey: More than 1 in 3 US Adults are Considering Nips/Tuckshttps://practicaldermatology.com/news/realself-survey-more-than-1-in-3-us-adults-are-considering-nipstucks/2457591/One in three adults (37 percent) in the US are considering at least one cosmetic treatment in the next 12 months, with significantly more considering nonsurgical procedures (34 percent) than surgical ones (24 percent), according to the
- Research Identifies Disparities in Outpatient Dermatologic Carehttps://practicaldermatology.com/news/research-identifies-disparities-in-outpatient-dermatologic-care/2457592/The odds of a black or Hispanic patient visiting an outpatient dermatologist are about half that of a white patient with the same skin condition, according to a new study in JAMA Dermatology. Patie